Organogenesis Holdings Inc.

Organogenesis Holdings Inc. (Nasdaq: ORGO) is a regenerative medicine company operating in the advanced wound care and surgical biologics sector. The company became publicly traded following its business combination with Avista Healthcare Public Acquisition Corp, a SPAC sponsored by Avista Capital Partners, which completed its IPO in 2018. Organogenesis filed an 8-K current report with the SEC on June 21, 2024, under accession number 0001193125-24-165670, disclosing material corporate developments to investors. The company continues to operate as a post-merger public entity focused on developing and commercializing regenerative medicine solutions across wound care, sports medicine, and spine applications. Sign up on SpacDesk for full filing data, sponsor history, and deal analytics on Organogenesis and hundreds of other SPAC-linked companies.